Megalabs

What Megalabs does

Megalabs (legal name MEGA LABS S.A.) is a privately-held Latin American pharmaceutical company headquartered in Montevideo, Uruguay, operating across more than 20 countries in the Americas. The company develops, manufactures, and commercializes a portfolio of over 1,800 pharmaceutical products spanning 15+ therapeutic areas including dermatology, gastroenterology, ophthalmology, pain and inflammation, cardio-metabolism, oncology, biosimilars, and consumer health (vitamins, nutraceuticals, OTC). Core technological capabilities are anchored in 12 coordinated R&D centers specializing in bioequivalents and biosimilars, with the company conducting approximately 40 bioequivalence studies annually to international GCP standards and operating EMA-equivalent manufacturing facilities. Flagship proprietary products include Enerceptan (the first Etanercept biosimilar approved in Argentina, developed entirely in Gema Biotech), ZVOPRAN/vonoprazan (the first P-CAB in Uruguay), and differentiated dermatology brands such as Umbrella, Hidrisage, and DS Laboratories.

The company's business model combines direct pharmaceutical sales, distribution agreements with international partners (IBSA across 18 countries, Formycon for aflibercept biosimilar, Medterra for CBD products), and a multi-brand consumer health segment. Revenue is generated through prescription and OTC channels via direct sales forces, pharmacy and retail chains, hospital procurement, and growing e-commerce distribution (notably for Prunelax in the US and Canada since 2007). Strategic expansion is executed through acquisitions of specialty pharma assets (DS Laboratories for dermatology, Dromex plant for ophthalmology manufacturing) and co-development alliances (Biolube for women's wellness). The company holds ISO/IEC 27001:2022 and ISO 13485:2016 certifications and operates a proprietary pharmacovigilance system (Centro Interamericano de Monitoreo) unique in the region. Led by CEO Gianclaudio Broggi, Megalabs employs over 8,000 people across its Latin American operations.

Name

Megalabs

Legal name

MEGA LABS S.A.

Website

https://megalabs.global

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Megalabs is a Uruguay-headquartered pharmaceutical company that develops, manufactures, and distributes over 1,800 products across dermatology, gastroenterology, ophthalmology, oncology, and consumer health in 20+ countries throughout the Americas, employing 8,000+ people.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical manufacturing
• Biosimilar development
• Bioequivalence studies
• Prescription medications
• OTC consumer health

Headquarters

HQ city

Montevideo

HQ country

Uruguay

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Megalabs generates revenue through the manufacture and sale of pharmaceutical products across 20+ Latin American countries. The company offers over 1800 products covering all therapeutic areas including dermatology, gastroenterology, pain, cardio-metabolism, neurosciences, ophthalmology, antiinfectives, and specialty products.
2. Distribution Agreements: Revenue is generated through distribution and licensing agreements with international pharmaceutical companies for their products in Latin American markets. Examples include agreements with IBSA (distribution in 18 countries), Formycon (aflibercept biosimilar for Latin America), and Medterra (CBD products).

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Megalabs is a Latin American pharmaceutical company that develops, manufactures, and distributes more than 1,800 pharmaceutical products across therapeutic areas including dermatology, gastroenterology, pain and inflammation, cardio-metabolism, ophthalmology, oncology, biosimilars, and consumer health. The company operates 12 coordinated R&D centers and produces bioequivalent and biosimilar medications at facilities certified to EMA, ISO 13485, and ISO 27001 standards, serving 20+ countries across the Americas.

Product overview

Megalabs is a diversified pharmaceutical company operating across Latin America with a portfolio of over 1,800 products covering therapeutic areas including Dermatology, Gastroenterology, Pain, Cardio-Metabolism, Neurosciences, Ophthalmology, Antiinfectives, Phytomedicine, High Specialization, Women's Health, Nutraceuticals, Respiratory, Vitamins, Genitourinary, and OTC. The company's portfolio includes multiple sub-brands and acquired brands such as Iclos (oncology/transplant/autoimmunity), Medihealth (dermatology), Poen (ophthalmology), and Hidrisage (dermo-cosmetics), alongside consumer health products like Victus Nutrición, Ciruelax, Abrilar, Umbrella, Prunelax, and Lactibón by Biolube. Megalabs operates through subsidiary companies across more than 20 countries in the Americas, with flagship products including Enerceptan (first Etanercept biosimilar in Latin America), ZVOPRAN (first P-CAB in Uruguay), and various specialty pharmaceutical formulations.

Differentiator

Problem solved

Functional benefit

Brands

• Iclos: Specializes in oncology, transplant and autoinmunity products
• Medihealth
• Poen
• Umbrella
• Hidrisage
• Victus
• Ciruelax
• Abrilar
• Enerceptan
• Lactibón by Biolube
• Prunelax
• Lumed
• Dolo K

Products and services

• Victus Nutrición Specialized clinical nutrition products for intestinal health, immune system support, diabetes, chronic wounds, renal insufficiency, and liver disease, sold under the Victus Nutrición brand across Latin America.
• Ciruelax Natural laxative with dried plum extract and herbs for occasional constipation, available in Latin America since 1987 and as a category leader.
• Abrilar Expectorant syrup of natural origin with demonstrated bronchodilator effect for rapid and safe cough relief.
• Umbrella Sun Protection High-protection sunscreen line with hypoallergenic formulas, dermatologically tested and certified by the Skin Cancer Foundation.
• Multiflora Line of prebiotics and probiotics specifically selected to treat digestive conditions.
• Piascledine Symptomatic treatment for osteoarthritis.
• Glaucotensil TD Treatment for elevated intraocular pressure in ocular hypertension, open-angle glaucoma, pseudoexfoliative glaucoma, and secondary open-angle glaucomas.
• Diclo K Treatment for pain relief in chronic inflammatory rheumatic diseases including rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, and spondylarthritis.
• Italdermol Topical treatment for burns of any degree, pressure ulcers, wounds, and wound healing, available in cream, gauze, and vaginal ovule formulations.
• Lumed Skin brightening and depigmentation treatment that lightens and unifies skin tone for spots caused by sun, age, or acne.
• Dolux Treatment for pain and inflammation in joints and muscles caused by osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout, and dental surgery.
• Enerceptan First biosimilar of Etanercept launched in the Latin American market, 100% developed at Gema Biotech, for treatment of autoimmune diseases including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, and plaque psoriasis.
• Erythropoietin Erythropoietin treatment for anemia in chronic renal insufficiency, HIV patients on zidovudine, chemotherapy-induced anemia, and to reduce allogeneic blood transfusion in surgery.
• Lactibón by Biolube Intimate feminine care line combining Lactibón's medical backing with Biolube's biotech innovation, launched in 11 Latin American markets as a 3-step routine (moisturizing cleansing lotion, refreshing spray, firming serum).
• Prunelax Natural laxative brand, category leader, available in major US retail chains since 2007 and in Latin America since 1987, with expansion into Canada.
• ZVOPRAN (vonoprazan) First and only P-CAB (Potassium-Competitive Acid Blocker) available in Uruguay for treatment of gastroesophageal reflux disease (GERD) and gastric/duodenal ulcers, planned for rollout across Latin America.
• Iclos (oncology, transplant, autoimmunity portfolio) Wholly-owned Megalabs subsidiary brand specializing in oncology, transplant, and autoimmunity products, with segregated oral oncological development area approved by EMA for mycophenolate mofetil manufacturing.
• Medihealth (dermatology portfolio) Wholly-owned Megalabs subsidiary brand offering dermatology therapeutic solutions for major skin pathologies with over 20 years of experience.
• Poen (ophthalmology portfolio) Ophthalmology reference brand within Megalabs, with manufacturing capabilities expanded through the Dromex plant acquisition in 2020.
• Hidrisage (dermo-cosmetics portfolio) Dermo-cosmetic line with a complete range of products to combat signs of cutaneous aging, formulated with bioavailable actives.

Quantifiable outcome

• Products available in 20+ countries occupying leadership positions
• +2 more outcomes

Named customers2 records

Segments6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core, strategic and minor.

• FormyconcoreStrategic or Co-development Partner · 16 October 2025Megalabs entered a licensing agreement with Formycon for distribution of their aflibercept biosimilar (Ahzantive) in Latin America. This partnership strengthens Megalabs' ophthalmology portfolio following Formycon's settlement with Regeneron for US market entry in Q4 2026.
• BiolubestrategicStrategic or Co-development Partner · 1 September 2025Alliance between Megalabs' Lactibón brand and Biolube to create Lactibón by Biolube, a new intimate wellness line for women. Combines Lactibón's medical backing with Biolube's biotech innovation, launching in 11 Latin American markets.
• IBSAcoreChannel Partner/ Reseller/ Distributor · 1 June 2021Distribution agreement signed between IBSA and Megalabs for distribution of three products in 18 Latin American countries starting late June 2021. Megalabs leverages its regional distribution network to expand IBSA's market presence.
• MedterracoreChannel Partner/ Reseller/ Distributor · 1 July 2020Megalabs signed agreement with Medterra to commercialize CBD-based products in Mexico, Argentina, and Brazil, expanding into the emerging CBD wellness market in Latin America.
• DeloitteminorImplementation/ SI/ Consulting PartnerPartnership with Deloitte for leadership academy program using Kaisen methodology to accelerate leadership development and talent identification across the organization.
• Instituto Polo Tecnológico de Pando / Universidad de la República / ANIIstrategicStrategic or Co-development PartnerPublic-private partnership for development of oral oncology products (pazopanib, erlotinib, pomalidomide) with support from Uruguay's National Agency for Research and Innovation.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Eurofarma Laboratórios: Brazil's largest privately-held pharmaceutical company with a broad generics, branded, and biosimilar portfolio across Latin America. Most direct comparable in scale (~10,000 employees, presence in 20+ countries), therapeutic breadth, and biosimilar/biotech ambition.
• Genomma Lab Internacional: Mexican pharmaceutical company focused on OTC, personal care, and generic pharmaceuticals across Latin America (listed on BMV). Comparable regional scale, multi-country distribution model, dermatology/consumer health overlap with Megalabs' Medihealth and Hidrisage brands.
• Aché Laboratórios Farmacêuticos: One of Brazil's largest pharmaceutical companies, with a strong branded generics, oncology, and dermatology franchise across Latin America. Comparable in therapeutic breadth, regional presence, and pivot toward biosimilars and specialty care.
• EMS Pharma: Brazil's largest pharmaceutical company by units sold, with a broad generics and branded generics portfolio spanning Latin America. Most directly comparable in generic/bioequivalent focus and broad therapeutic coverage.
• Laboratorios Roemmers: Leading Argentine pharmaceutical company with branded prescription, OTC, and specialty products across Latin America. Comparable in therapeutic breadth, regional presence, and emphasis on bioequivalence/specialty development.
• Biolab Farmacêutica: Brazilian pharmaceutical company with strong cardiology, dermatology, and women's health franchises in Latin America. Therapeutic-area overlap with Megalabs' cardio-metabolism and dermatology segments.
• Laboratorios Bagó: Argentine pharmaceutical multinational with branded generics, specialty, and OTC products across Latin America. Comparable regional distribution footprint and branded-generic strategy.
• Laboratorios Richmond: Argentine pharmaceutical company focused on branded generics, biosimilars, and specialty products with regional LatAm distribution. Most directly comparable as a LatAm biosimilar developer.

Broad incumbents

• Sandoz (Novartis): Global leader in generics and biosimilars with significant Latin American presence. Competes with Megalabs in biosimilars (Enerceptan territory) and broad generics, but operates as part of a much larger global portfolio.
• Teva Pharmaceutical: World's largest generic drug manufacturer with established Latin American operations. Competes in biosimilars, generics, and specialty; broad incumbent rather than regional specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries12 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Megalabs